• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Sodium-glucose co-transporter 2 inhibitors: drugs with multiple effects, but which one is relevant to heart failure with preserved ejection fraction? Letter regarding the article 'Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial'.

作者信息

Kokhan Elizaveta, Kiyakbaev Gayrat, Medovchshikov Vadim

机构信息

Sechenov University, Moscow, Russia.

City Clinical Hospital #17, Moscow, Russia.

出版信息

Eur J Heart Fail. 2022 Jul;24(7):1323-1324. doi: 10.1002/ejhf.2466. Epub 2022 Mar 9.

DOI:10.1002/ejhf.2466
PMID:35238461
Abstract
摘要

相似文献

1
Sodium-glucose co-transporter 2 inhibitors: drugs with multiple effects, but which one is relevant to heart failure with preserved ejection fraction? Letter regarding the article 'Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial'.钠-葡萄糖协同转运蛋白2抑制剂：具有多种作用的药物，但哪一种与射血分数保留的心力衰竭相关？关于文章《恩格列净对射血分数保留的心力衰竭的早期获益：EMPEROR-Preserved试验的见解》的信函
Eur J Heart Fail. 2022 Jul;24(7):1323-1324. doi: 10.1002/ejhf.2466. Epub 2022 Mar 9.
2
Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.恩格列净对射血分数保留的慢性心力衰竭患者发病率和死亡率影响的评估：EMPEROR-Preserved 试验的原理和设计。
Eur J Heart Fail. 2019 Oct;21(10):1279-1287. doi: 10.1002/ejhf.1596. Epub 2019 Sep 16.
3
Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).恩格列净对射血分数降低的心力衰竭合并 2 型糖尿病或糖尿病前期患者左心室容积的影响（SUGAR-DM-HF）。
Circulation. 2021 Feb 9;143(6):516-525. doi: 10.1161/CIRCULATIONAHA.120.052186. Epub 2020 Nov 13.
4
Sodium-Glucose Co-transporter 2 Inhibitors in Patients with Heart Failure with Preserved Ejection Fraction: Proposed Mechanisms, Recent Evidence, and Clinical Implications.钠-葡萄糖共转运蛋白 2 抑制剂在射血分数保留的心力衰竭患者中的应用：作用机制、最新证据和临床意义。
Cardiol Rev. 2024;32(3):263-266. doi: 10.1097/CRD.0000000000000501. Epub 2022 Dec 28.
5
A mechanistic rationale for the investigation of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction. Letter regarding the article 'Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial'.对射血分数保留的心力衰竭患者进行钠-葡萄糖协同转运蛋白2抑制剂研究的机制原理。关于文章“EMPEROR-Preserved试验中射血分数保留的心力衰竭患者的基线特征”的信函
Eur J Heart Fail. 2021 May;23(5):841. doi: 10.1002/ejhf.2091. Epub 2021 Feb 4.
6
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial.在 EMPEROR-Preserved 试验中射血分数保留型心力衰竭患者的基线特征。
Eur J Heart Fail. 2020 Dec;22(12):2383-2392. doi: 10.1002/ejhf.2064.
7
Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.恩格列净对射血分数降低的慢性心力衰竭患者发病率和死亡率影响的评估：EMPEROR-Reduced 试验的原理和设计。
Eur J Heart Fail. 2019 Oct;21(10):1270-1278. doi: 10.1002/ejhf.1536. Epub 2019 Jul 16.
8
SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction.钠-葡萄糖协同转运蛋白 2 抑制剂与射血分数保留的心力衰竭。
Heart Fail Clin. 2022 Oct;18(4):579-586. doi: 10.1016/j.hfc.2022.03.010.
9
Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population.达格列净和恩格列净在真实心力衰竭人群中的应用资格。
J Card Fail. 2022 Jul;28(7):1050-1062. doi: 10.1016/j.cardfail.2022.04.011. Epub 2022 May 10.
10
Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial.恩格列净对射血分数保留的心力衰竭患者心力衰竭恶化事件的影响：EMPEROR-Preserved 试验。
Circulation. 2021 Oct 19;144(16):1284-1294. doi: 10.1161/CIRCULATIONAHA.121.056824. Epub 2021 Aug 29.

引用本文的文献

1
Empagliflozin in the treatment of heart failure and type 2 diabetes mellitus: Evidence from several large clinical trials.恩格列净在心力衰竭和 2 型糖尿病治疗中的应用：来自几项大型临床试验的证据。
Int J Med Sci. 2022 Jun 21;19(7):1118-1121. doi: 10.7150/ijms.72772. eCollection 2022.